Title:
Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study
Published:
The New England Journal of Medicine (To the Editor), 2 June 2021
From the article:
Rare thromboembolic events have been observed during the vaccination rollout, which have prompted cautionary pauses in vaccinations by some regulatory authorities, including the South Africa Health Products Regulatory Authority.1,2 Here, we report interim safety data from the first 288,368 participants who were vaccinated with Ad26.COV2.S in the Sisonke study — an open label, single-group, phase 3b implementation study to monitor the effectiveness of the single-dose Ad26.COV2.S vaccine among 500,000 health care workers in South Africa (ClinicalTrials.gov number, NCT04838795. opens in new tab).